Text Size

Using Repetitive Transcranial Magnetic Stimulation (rTMS) in the Rehabilitation of Chronic Spatial Neglect After Stroke (NEGLECT)

This study is currently recruiting participants.
Verified May 2011 by Assistance Publique - Hôpitaux de Paris
Sponsor:
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT01000103
First received: October 21, 2009
Last updated: October 28, 2011
Last verified: May 2011
History of Changes
  Purpose

Visuospatial neglect is a common neurological symptom which appears following strokes on regions of the right hemisphere of the brain. It affects patient's self representation and awareness of the space, impairing functional rehabilitation and adaptation back to a normal life. The primary purpose of this protocol is to assess the impact of 10 daily sessions of a non-invasive brain stimulation technique, low frequency repetitive Transcranial Magnetic Stimulation (rTMS), applied on the intact hemisphere of the brain to treat post stroke visuospatial neglect at the chronic stage. The hypothesis is that a regime of real but not sham rTMS on the left posterior parietal cortex of the brain will long-lastingly ameliorate visuospatial neglect in stroke patients as revealed by clinical paper-and-pencil and computer-based tests assessing search, detection and discrimination of stimuli presented in different areas of the visual field.


Condition Intervention Phase
Cerebrovascular Disorders
Cerebral Stroke
VISIO-spatial Neglect
VISUO-spatial Extinction
 Device: Real rTMS
Device: Sham rTMS
 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Using Repetitive Transcranial Magnetic Stimulation (rTMS) in the Rehabilitation of Chronic Spatial Neglect After Stroke: A Double Blind Study

Resource links provided by NLM:

MedlinePlus related topics: Rehabilitation
U.S. FDA Resources

Further study details as provided by Assistance Publique - Hôpitaux de Paris:

Primary Outcome Measures:
  • Changes in the Spatial Bias Compound Score (SBCS). Such score is calculated on the basis of the result of 4 subtests [ Time Frame: between pre (baseline) and post 10 days of rTMS treatment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Changes in Catherine BERGEGO Scale and-or equivalent ecological test [ Time Frame: between pre (baseline) and every subsequent evaluation ] [ Designated as safety issue: No ]
  • Changes in the percentage of correct target detections vs. total [ Time Frame: between pre (baseline) and every subsequent evaluation ] [ Designated as safety issue: No ]
  • Changes in the Normalized reaction time of correct detections [ Time Frame: between pre (baseline) and every subsequent evaluation ] [ Designated as safety issue: No ]
  • potential clinically relevant side-effect caused by the use of TMS in terms of neurological manifestations such as: seizure, occurrence of additional stroke, or signs of enhanced intracranial pressure. [ Time Frame: During rTMS treatment and the 6 months follow-up ] [ Designated as safety issue: Yes ]
  • changes in cognitive functions processed by the intact left parietal cortex [ Time Frame: between baseline and every subsequent evaluation, during the 6 months follow-up ] [ Designated as safety issue: Yes ]
  • Changes of the main cognitive domains and depression status according to the Mini-Mental test and Hamilton depression scale [ Time Frame: between pre (baseline) and every subsequent evaluation ] [ Designated as safety issue: Yes ]
  • Correlation between treatment efficacy and lesion location and extent [ Time Frame: Any time after the end of rTMS treatment ] [ Designated as safety issue: No ]
  • Correlation between treatment efficacy and severity of Neglect and other associated clinical deficits [ Time Frame: Any time after the end of rTMS treatment ] [ Designated as safety issue: No ]
  • Correlation between treatment efficacy and rTMS parameters and patient's cortical excitability and sensations [ Time Frame: Any time after the end of rTMS treatment ] [ Designated as safety issue: No ]
  • Correlation between treatment efficacy and daily activities with potential impact on Neglect [ Time Frame: Any time after the end of rTMS treatment ] [ Designated as safety issue: No ]
  • Evaluation of SBCS and its subscores at each follow-up visits [ Time Frame: 5 days, 10 days, 15 days, 20 days, 27 days, 40 days, 70 days, 130 days and 190 days after 1st rTMS session. ] [ Designated as safety issue: No ]
  • Changes in neurological conditions according to: Rankin, Barthel and NIH SS scores [ Time Frame: Between baseline and every subsequent evaluation ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 148
Study Start Date: March 2010
Estimated Study Completion Date: February 2014
Estimated Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1: Real rTMS treatment
Transcranial Magnetic Stimulation, in a low frequency (1 Hz) continuous train of 20 minutes (1200 pulses)
 Device: Real rTMS
Transcranial Magnetic Stimulation, in a low frequency (1 Hz) continuous train of 20 minutes (1200 pulses)
Sham Comparator: 2: Sham rTMS treatment
Simulation of rTMS
 Device: Sham rTMS
two TMS coils will be used: a passive one which is placed flat on top of the "actively" targeted region which remains unplugged and generates a continuous scalp tactile sensation, and an active one located at a prudential distance from the scalp, which will deliver active pulses and its accompanying sensations

Detailed Description:

Scientific aims and goals:

The long-term goal aim of this application is to provide evidence of the role of a non-invasive neuromodulation technique such as rTMS in the treatment of chronic neurological sequels generated after strokes in human patients. Such interventions are based in an "at will" modulation the level of activity in intact regions, resulting in an enhancement of excitatory projections or the suppression of inhibitory influences driven through spared connectivity. They result in activity increases of the stroke surviving neurons, allowing the re-emergence of function after brain damage. Such principles can be applied to different sorts of neurological sequels for which the underlying connectivity and its post-stroke status is well known. In this specific project, we propose the use of low frequency rTMS on the intact left posterior parietal cortex (in the intraparietal sulcus, IPS) to improve the symptoms of visuospatial neglect derived form right stroke injuries including the posterior parietal cortex. Such project is based in the interhemispheric rivalry hypothesis, according to which, spatial neglect is in part caused by the over inhibition exerted from the intact left parietal cortex onto the injured left homologue regions, which are mediated by well-known overall inhibitory transcallosal projections between the left and the right hemispheres. According to this hypothesis and preliminary data, the reduction of the left parietal disinhibition should result into a lesser degree of suppression exerted by the intact left hemisphere sites onto the right injured parietal areas, process which will along the emergence of activity.In this context, we defined a primary aim accompanied by two secondary aims, which will be tackled in parallel:Primary AIMS AIM1: To assess the effects of repetitive Transcranial Magnetic Stimulation (rTMS) in the treatment of chronic visuospatial neglect generated by stroke Secondary AIMS AIM 2: To assess the durability of such a recovery over time once the treatment is completed and discontinued AIM 3: To further assess the safety of such therapeutic approach based in the deactivation of an intact -but hyperexcited region- holding connectivity with the damaged area.

Evaluation criteria Main criteria -Changes in the Spatial Bias Compound Score (SBCS) between pre (baseline) and post 10 days of rTMS treatment Such score is calculated on the basis of the result of 4 subtests which include: (1) bells cancellation task, (2) a copy of the GAINOTTI figure, (3) identification of overlapping figures, and (4) line bisection, according to the following formula (SBCS=λ=ln(XR/XL), considering the identification or copying of elements presented on the right or the left visual fields of the patient. The subtests of the SBCS will be also individually assessed and followed.

Secondary criteria

  1. Efficacy criteria
  2. Safety criteria
  3. Predictive factors assessmentStudy population and duration of studyWe will study a population of stroke patients with chronic signs of hemispatial neglect with at least 3 months of evolution (n=148, 2 groups of 74 patients) recruited across 48 months at an approximate rate of 37 patients /year.
  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Unilateral right hemisphere stroke
  2. Visuospatial neglect or extinction at the time of entry, as determined by at least 1 test of the battery (BEN) displaying pathological scores (cut off values as defined in AZOUVI et al. JNNP 2004, Table 1), or an ECB test, score > 8
  3. A period of evolution of at least 3 months since stroke event
  4. Age between 18 and 75 years old
  5. Affiliation to Social Security system
  6. Informed consent signature

Exclusion Criteria:

  1. Criteria related to the stroke:

    • Bilateral stroke lesions: left hemispheric focal lesion excluding leucoaraiosis or mild lesions of the white matter

  2. Criteria related to rTMS:

    • Metal in the head, or a history of prior neurosurgical procedures
    • Ferromagnetic bioimplants activated by any electronic, mechanical or magnetic means such as: cochlear implants, pacemakers, medication pumps, vagal stimulators, deep brain stimulators, neurostimulators, bio stimulators, or ventriculoperitoneal shunts.
    • Prior history of seizures or seizure events following the stroke requiring the use of antiepileptic drugs
    • Pregnancy (by history or positive urine pregnancy test)
    • A urine pregnancy test will be done on all women of childbearing potential (those who have started menstruating up until they have stopped menstruating) prior to each MRI session, to rule out pregnancy.
    • Diagnosis of tinnitus
    • Participation in any experimental neglect rehabilitation project for at least 5 weeks before and 2 weeks after the stimulation, or during the 6 months of follow-up.
    • Prior participation in TMS based treatments or experiments

  3. Criteria related to feasibility:

    • Incapacity to follow and complete the stimulation and follow-up protocol
    • Other medical cerebral conditions other than the condition studied in the present protocol
    • Any general medical condition, which could potentially interfere with clinical progression
    • Any incapacitating psychiatric conditions, including significant history of substance abuse and severe depression
    • Chronic treatment with medications that might modify cortical excitability
    • Subjects with visual impediments that would limit our ability to obtain reliable testing
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01000103

Contacts
Contact: Pascale PRADAT-DIEHL, MD-PhD +33 (0)1 42 16 11 09 pascale.pradat@psl.aphp.fr
Contact: Antoni VALERO-CABRE, MD-PHD +33 (0)1 42 16 00 62/64 avalerocabre@gmail.com

Locations
France
Hôpital de la Salpétrière Recruiting
Paris, France, 75013
Contact: Pascale Pradat-Diehl, MD-PhD     +33(0)1 42 16 11 09     pascale.pradat@psl.aphp.fr    
Contact: Antoni VALERO-CABRE, MD-PhD     +33 (0)1 42 16 00 62/64     avalerocabre@gmail.com    
Principal Investigator: Pascale PRADAT-DIEHL, MD-PhD            
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Investigators
Study Director: Pascale PRADAT-DIEHL, MD-PhD Assistance Publique - Hôpitaux de Paris
Principal Investigator: Antoni VALERO-CABRE, MD-PhD France: Centre National de la Recherche Scientifique
  More Information

No publications provided

Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT01000103     History of Changes
Other Study ID Numbers: P071238, ID RCB 2009-A00280-57
Study First Received: October 21, 2009
Last Updated: October 28, 2011
Health Authority: France: Ministry of Health

Keywords provided by Assistance Publique - Hôpitaux de Paris:
Stroke
Visuospatial neglect
Visuospatial extinction
Transcranial Magnetic Stimulation (TMS)
Non-invasive brain stimulation
 Neuromodulation
Brain parietal cortex
Neurological sequels
Cognitive rehabilitation

Additional relevant MeSH terms:
Cerebrovascular Disorders
Stroke
Cerebral Infarction
Perceptual Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
 Vascular Diseases
Cardiovascular Diseases
Brain Infarction
Brain Ischemia
Neurobehavioral Manifestations
Neurologic Manifestations
Signs and Symptoms

ClinicalTrials.gov processed this record on May 21, 2013